Summary:
Double-Blind, Single and Multiple Dose Study to Determine Pharmacodynamic Markers, Pharmacokinetic Parameters, and Safety of ALTO-203 in Patients with Major Depressive Disorder
Qualified Participants Must:
• Be aged 25 to 64 years old
• have a diagnosis of MDD
• have presence of anhedonia symptoms
• not be taking any antidepressant medication
Qualified Participants May Receive:
Study-related care
Investigational Treatment or Placebo
Compensation up to $1850